Literature DB >> 30474721

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol.

Vicenç Torrente-Segarra1, Manuel Fernandez Prada2, Rosa Expósito Moliner3, Noemí Patricia Garrido Puñal4, Amalia Sánchez-Andrade Fernández5, José Ramón Lamua Riazuelo6, Alejandro Olivé7, Juan Víctor Tovar Beltrán8.   

Abstract

Entities:  

Keywords:  Effectiveness; Rheumatoid arthritis; Safety; Tumor necrosis factor inhibitors

Mesh：

Substances：

Year:  2018        PMID： 30474721     DOI： 10.1007/s00296-018-4205-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  8 in total

1.  Survival and safety of treatment with infliximab in the elderly population.

Authors:  H Chevillotte-Maillard; P Ornetti; R Mistrih; C Sidot; J Dupuis; J-A Dellas; C Tavernier; J F Maillefert
Journal:  Rheumatology (Oxford)       Date:  2005-02-10       Impact factor: 7.580

2.  The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study.

Authors:  Marita Cross; Emma Smith; Damian Hoy; Loreto Carmona; Frederick Wolfe; Theo Vos; Benjamin Williams; Sherine Gabriel; Marissa Lassere; Nicole Johns; Rachelle Buchbinder; Anthony Woolf; Lyn March
Journal:  Ann Rheum Dis       Date:  2014-02-18       Impact factor: 19.103

3.  Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis.

Authors:  Atsuko Murota; Yuko Kaneko; Kunihiro Yamaoka; Tsutomu Takeuchi
Journal:  J Rheumatol       Date:  2016-09-01       Impact factor: 4.666

4.  Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.

Authors:  Leticia Leon; Alejandro Gomez; Cristina Vadillo; Esperanza Pato; Luis Rodriguez-Rodriguez; Juan Angel Jover; Lydia Abasolo
Journal:  Clin Exp Rheumatol       Date:  2017-06-06       Impact factor: 4.473

5.  [Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis].

Authors:  Jesús Tornero Molina; Raimon Sanmartí Sala; Vicente Rodríguez Valverde; Emilio Martín Mola; José Luis Marenco de la Fuente; Isidoro González Álvaro; Santiago Muñoz Fernández; Juan Gómez-Reino Carnota; Luis Carreño Pérez; Enrique Batlle Gualda; Alejandro Balsa Criado; José Luis Andreu; José María Alvaro-Gracia; Juan Antonio Martínez López; Estíbaliz Loza Santamaría
Journal:  Reumatol Clin       Date:  2009-12-06

6.  Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.

Authors:  Stéphane Genevay; Axel Finckh; Adrian Ciurea; Anne-Marie Chamot; Diego Kyburz; Cem Gabay
Journal:  Arthritis Rheum       Date:  2007-05-15

7.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  Edward Keystone; Désireé van der Heijde; David Mason; Robert Landewé; Ronald Van Vollenhoven; Bernard Combe; Paul Emery; Vibeke Strand; Philip Mease; Chintu Desai; Karel Pavelka
Journal:  Arthritis Rheum       Date:  2008-11

8.  Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

Authors:  Edward Keystone; Robert Landewé; Ronald van Vollenhoven; Bernard Combe; Vibeke Strand; Philip Mease; Laura Shaughnessy; Brenda VanLunen; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-08-05       Impact factor: 19.103
  8 in total
  1 in total

1.  Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.

Authors:  A Ruggiero; G Fabbrocini; E Cinelli; S S Ocampo Garza; E Camela; M Megna
Journal:  Clin Exp Dermatol       Date:  2021-11-17       Impact factor: 4.481
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.